Harbor Capital Advisors’s Freeline Therapeutics Holdings plc American Depositary Shares FRLN Stock Holding History

Harbor Capital Advisors’s Portfolio FRLN Stock Details FRLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-20,352	Closed	-$129K	–	881
2023 Q4	$129K	Buy	20,352 +7,848	+63%	+$42K	0.02%	403
2023 Q3	$53K	Buy	12,504 +1,795	+17%	+$7.1K	0.01%	432
2023 Q2	$27.6K	Buy	10,709 +3,527	+49%	+$13.9K	0.01%	546
2023 Q1	$49.6K	Sell	7,182 -1,429	-17%	-$11.1K	0.01%	245
2022 Q4	$64.3K	Sell	8,611 -186	-2%	-$1.77K	0.06%	154
2022 Q3	$92K	Sell	8,797 -974	-10%	-$12.7K	0.08%	87
2022 Q2	$129K	Buy	9,771 +126	+1%	+$1.62K	0.1%	148
2022 Q1	$162K	Sell	9,645 -2,523	-21%	-$46.8K	0.08%	128
2021 Q4	$360K	Buy	+12,168	New	+$497K	0.13%	91

Harbor Capital Advisors's FRLN Position: Q1 2024 in Review

Harbor Capital Advisors sold out of Freeline Therapeutics Holdings plc American Depositary Shares (FRLN) in Q1 2024, closing a stake of 20,352 shares — an estimated $129K sold.

Harbor Capital Advisors first reported a position in FRLN in Q4 2021 and held it in 9 quarters. The position peaked at $360K in Q4 2021. 0 funds tracked by Wall St. Rank hold FRLN as of Q1 2024.

Harbor Capital Advisors reported no remaining Freeline Therapeutics Holdings plc American Depositary Shares position as of Q1 2024 after selling out during the quarter.
Harbor Capital Advisors sold 20,352 Freeline Therapeutics Holdings plc American Depositary Shares shares in Q1 2024, an estimated $129K.
Harbor Capital Advisors first reported a position in Freeline Therapeutics Holdings plc American Depositary Shares in Q4 2021 and held it in 9 quarters.
Harbor Capital Advisors's Freeline Therapeutics Holdings plc American Depositary Shares position peaked at $360K in Q4 2021.
0 funds tracked by Wall St. Rank held Freeline Therapeutics Holdings plc American Depositary Shares as of Q1 2024.

Based on Harbor Capital Advisors's 13F filing for Q1 2024, filed 13 May 2024.